| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
AspirinWorks® 11-Dehydrothromboxane B2 (11-dhTXB2) with Creatinine
Test Code16174
CPT Codes
84431, 82570
Preferred Specimen
4 mL random preserved urine in BD C&S Urine Vacutainer® (gray-top) tube
Minimum Volume
3 mL
Other Acceptable Specimens
4 mL random urine collected in a cherry red/yellow-top BD Vacutainer preservative tube • 4 mL random urine collected in a yellow-top plain urine tube
Instructions
Recommend using BD C&S Vacutainer® tube for collection (Quest Supply # 141974).
If urine is not collected in the preferred or alternative specimen tubes, it must be poured off into these tubes within 4 hours of collection.
It is not recommended to test individuals suffering from urinary tract infections, severe liver disease, or end stage renal disease.
If urine is not collected in the preferred or alternative specimen tubes, it must be poured off into these tubes within 4 hours of collection.
It is not recommended to test individuals suffering from urinary tract infections, severe liver disease, or end stage renal disease.
Transport Temperature
Room temperature
Specimen Stability
BD C&S Vacutainer tube and cherry red (yellow-top) tube
Room temperature: 7 days
Refrigerated: 14 days
Frozen: 90 days
Plain (yellow-top) tube
Room temperature: 7 days
Refrigerated: 14 days
Frozen: 6 months
Room temperature: 7 days
Refrigerated: 14 days
Frozen: 90 days
Plain (yellow-top) tube
Room temperature: 7 days
Refrigerated: 14 days
Frozen: 6 months
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Excessive sediment • Blood • Insoluble materials
Methodology
Calculation (CALC) • Enzymatic • Immunoassay (IA)
FDA Status
The performance characteristics of this test were determined by the Cleveland HeartLab, Inc. The Cleveland HeartLab is authorized under Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity clinical laboratory testing.
Setup Schedule
Set up: Mon-Fri; Report available: 1-5 days
Clinical Significance
Aspirin (which inhibits platelet cyclooxygenase) reduces the risk of thrombosis in cardiovascular disease by impairing platelet function. Patients who do not respond to the platelet inhibitory effects of aspirin are designated as "aspirin resistant". The measurement of 11-dhTXB2 in urine (the principal metabolite of platelet cyclooxygenase derived thromboxane B2) may be used in individuals with cardiovascular disease prior to initiation of aspirin therapy, or in individuals non-responsive to aspirin therapy.
